A dose-expansion phase study in advanced endometrial cancer reported durable tumor shrinkage when an oral Wnt-blocking agent was combined with lenvatinib after prior immunotherapy failure. The findings, published in EClinicalMedicine, describe activity in women whose disease had already not responded to chemotherapy and checkpoint-based treatment. The trial pairs a targeted strategy aimed at blocking a tumor-intrinsic signaling switch with lenvatinib, an established therapy in this setting. For patients with limited options post-immunotherapy, the durability signal may influence how clinicians consider next-line combinations. The results add to the growing body of research exploring Wnt-pathway inhibition as a mechanism to deepen responses when standard immunotherapy-based regimens stall.